| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() The U.K. Approves Copaxone (Glatiramer Acetate) For Relapsing-remitting Multiple Sclerosis JERUSALEM, ISRAEL -- August 14, 2000 -- Teva Pharmaceutical Industries, Ltd., announced that Copaxone® (glatiramer acetate for injection) was approved for marketing in the U.K. This is the first approval in a major European market and enables Teva to file for approval all over the E.U. under the mutual recognition procedure. Teva plans to launch Copaxone in the U.K. market in the beginning of the fourth quarter of this year. Copaxone is indicated for reduction in frequency of relapses in relapsing-remitting multiple sclerosis. Eli Hurvitz, President and Chief Executive Officer commented: "We are excited to have received this approval and even more with the opportunity it represents for the rest of the European market." Teva is currently preparing the filing under the European Mutual Recognition Procedure to make Copaxone available in the remainder of the European Union. The U.K. has agreed to act as the reference member state. The successful completion of this procedure is expected to enable Teva to launch Copaxone in the E.U. around mid 2001. Related Links: Copaxone (glatiramer acetate) and Teva Pharmaceutical Industries, Ltd.
|